Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Laserscope (NASDAQ LSCP) -- Ignore unavailable to you. Want to Upgrade?

To: dylan murphy who wrote (307)	2/18/2005 1:47:20 AM
From: Dick Martin	Read Replies (1) \| Respond to of 314

We could see another good advance from these levels, earnings should be out soon, here is the latest press release. On the long haul this stock could go and go. Dick Laserscope Announces Introduction of Solis(TM) Aesthetic Treatment Platform Thursday February 17, 4:08 pm ET Solis(TM) Addresses Major Trend in Aesthetic Light-Based Therapies Worldwide SAN JOSE, Calif., Feb. 17 /PRNewswire-FirstCall/ -- Laserscope (Nasdaq: LSCP - News), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today reported that it will introduce the next generation of light-based aesthetic treatment devices, called the Solis(TM), at the American Academy of Dermatology Annual Meeting taking place in New Orleans from February 18th through February 22nd. "The Solis platform will be positioned to complement our existing aesthetic product lines and will address a significant need in the market," said Eric Reuter, Laserscope President and CEO. "Overall practice revenue for physicians of all specialties performing light-based cosmetic procedures continues to climb in the U.S. and internationally. However, the average revenue per procedure and per physician for these treatments is falling as the market becomes more competitive and patients have a wider range of choices. The Solis addresses this trend by offering among the fastest treatment speeds for large body areas of any available device. For instance, an average man's back can be treated with the Solis for hair removal in as little as 15 minutes. This is from 50% to 500% faster than any of the leading laser and light-based treatment devices available on the market today. "The addressable market includes not only new practitioners who are considering offering cosmetic treatments to their patients, but also the thousands of physicians who have purchased devices in the past that are no longer competitive in the current market environment. We believe the Solis will give our customers a wide range of choices and will fill out our aesthetic treatment product line very well. It is specifically designed for those customers who want to do large body areas very quickly. We are very excited to be able to bring this innovative new technology to our existing and new customers." Robert Mann, Laserscope's Group Vice President, Global Sales and Marketing added, "The unprecedented speed, ease of use and efficacy of Solis delivers a real economic benefit to the physician and ultimately the patient. The Solis is another example of Laserscope's commitment to provide profound clinical and economic solutions to physicians worldwide." About Laserscope Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. More information about Laserscope can be found on the Company's web site at www.laserscope.com. Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. These risks are detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's public disclosure filings with the SEC, including the most recent Annual Report on Form 10-K and the most recent Forms 10-Q are available upon request from its Investor Relations Department and online at the company's web site. At Laserscope: At Financial Relations Board: Eric Reuter, President & CEO Tricia Ross, Analyst/Investor Contact Dennis LaLumandiere, CFO (617) 520-7064 (408) 943-0636 Laurie Berman, General Information (310) 854-8315